Drug Profile
Research programme: triapine prodrug therapy - Vion
Latest Information Update: 04 Dec 2007
Price :
$50
*
At a glance
- Originator Vion Pharmaceuticals
- Class
- Mechanism of Action Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 29 Mar 2001 Preclinical development for Cancer in USA (Unknown route)